Literature DB >> 10940745

Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome.

T K Mattoo1, M A Mahmoud.   

Abstract

Relapses are common in children with idiopathic nephrotic syndrome, and this prospective study looks into the possibility of decreasing the frequency of relapses in a selected group of such patients. The study includes 36 children with a steroid-dependent, relapsing nephrotic syndrome on a maintenance prednisone therapy of about 0.5 mg/kg every other day. They were prospectively divided into two groups with comparable age and sex distribution and the number of those who had previously received cyclophosphamide therapy. Group 1 patients were advised to take daily prednisone for 5 days, starting at the time of the onset of an upper respiratory tract infection (URI). No such advice was given to those in group 2, and they remained on alternate-day prednisone during URI. At the end of a 2-year follow-up period, the total number of relapses in group 1 was 40 with a mean of 2.2 +/- 0.87 per patient as compared with 99 with a mean of 5.5 +/- 1.33 per patient in group 2 (p = 0.04). We conclude that an increased maintenance prednisone during URI helps decrease significantly the number of relapses in those on alternate-day therapy. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940745     DOI: 10.1159/000045684

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  20 in total

Review 1.  Evidence-based management of steroid-sensitive nephrotic syndrome.

Authors:  Elisabeth M Hodson; Jonathan C Craig; Narelle S Willis
Journal:  Pediatr Nephrol       Date:  2005-06-21       Impact factor: 3.714

2.  Circannual variation in the onset and relapse of steroid-sensitive nephrotic syndrome.

Authors:  Shin-ichi Toyabe; Makiko Nakamizo; Makoto Uchiyama; Kouhei Akazawa
Journal:  Pediatr Nephrol       Date:  2005-02-18       Impact factor: 3.714

3.  Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.

Authors:  Menka Yadav; Aditi Sinha; Priyanka Khandelwal; Pankaj Hari; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2018-09-07       Impact factor: 3.714

4.  Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.

Authors:  Asiri S Abeyagunawardena; R S Thalgahagoda; Pathum V Dissanayake; Shamali Abeyagunawardena; Y A Illangasekera; Umeshi I Karunadasa; Richard S Trompeter
Journal:  Pediatr Nephrol       Date:  2017-03-24       Impact factor: 3.714

Review 5.  Corticosteroid therapy for nephrotic syndrome in children.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-03-18

Review 6.  How randomised trials have improved the care of children with kidney disease.

Authors:  Elisabeth M Hodson; Jonathan C Craig
Journal:  Pediatr Nephrol       Date:  2016-08-03       Impact factor: 3.714

Review 7.  Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.

Authors:  Rebecca M Lombel; Debbie S Gipson; Elisabeth M Hodson
Journal:  Pediatr Nephrol       Date:  2012-10-03       Impact factor: 3.714

8.  Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial.

Authors:  Ashima Gulati; Aditi Sinha; Vishnubhatla Sreenivas; Aparna Math; Pankaj Hari; Arvind Bagga
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-16       Impact factor: 8.237

Review 9.  The management of idiopathic nephrotic syndrome in children.

Authors:  Elisabeth Hodson
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 10.  Corticosteroid therapy for nephrotic syndrome in children.

Authors:  Deirdre Hahn; Susan M Samuel; Narelle S Willis; Jonathan C Craig; Elisabeth M Hobson
Journal:  Cochrane Database Syst Rev       Date:  2020-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.